Abbott Laboratories stock holds near $108 after strong Q2

Published on 09/06/2026 at 09:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock traded at $108.29 on September 4, 2026, after a July 16 quarter that delivered $12.59 billion in revenue and $1.31 EPS.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories stock (US0028241000) traded at $108.29 on September 4, 2026, after closing down 0.46 percent on the session and carrying a market capitalization of $187.38 billion. The July 16, 2026 quarter added $12.59 billion in revenue and $1.31 in adjusted EPS, with revenue up 13.0 percent from a year earlier.

July figures still set the tone

According to a MarketBeat report, Abbott beat the consensus estimate of $1.28 EPS by $0.03 in the quarter ended July 16, 2026. The same report said net margin was 11.65 percent and return on equity was 17.69 percent.

The quarter also came with clear guidance: management set Q3 2026 EPS guidance at 1.38 to 1.46 and FY 2026 guidance at 5.45 to 5.60. That makes the comparison point precise for investors: $1.31 in the quarter versus $1.28 expected, and 13.0 percent revenue growth year over year.

Consensus stays supportive

MarketBeat also showed a consensus target price of $119.50 and a consensus rating of Moderate Buy on Abbott Laboratories stock. Against the September 4 price of $108.29, that implies an upside gap of 10.4 percent, a simple spread that keeps the valuation debate open.

Free cash flow adds a second operating reference. StockTitan said Abbott Laboratories reported $916.0 million in free cash flow in Q1 2026, down 1.8 percent from the same quarter a year earlier.

Go deeper

Abbott earnings and cash flow

The quarter ended July 16, 2026, and the Q1 2026 cash flow line give investors two different ways to judge the stock.

Diagnostics and nutrition

Abbott's product mix still spans diagnostics, medical devices, nutrition, and established pharmaceuticals, which helps explain why the quarterly revenue base stayed above $12 billion. For the stock, the relevant point is not the brand spread but the combination of 13.0 percent revenue growth, 11.65 percent net margin, and a Q3 2026 EPS guide of 1.38 to 1.46.

Stock near the $108 mark

Abbott Laboratories stock was at $108.29 on September 4, 2026, with a market capitalization of $187.38 billion and a 52-week range of $110.86 to $137.49 on the same MarketBeat snapshot. That leaves the shares below both the recent trading high and the consensus target of $119.50.